Slingshot members are tracking this event:

Loxo Oncology Receives Breakthrough Therapy Designation from FDAfor LOXO-101

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK), “for the treatment of unresectable or metastatic solid tumors with NTRK-fusion proteins in adult and pediatric patients who require systemic therapy and who have either progressed following prior treatment or who have no acceptable alternative treatments.”
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 13, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Loxo-101, Breakthrough Therapy Designation, Metastatic Solid Tumors, Ntrk-fusion Proteins